Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canrenone add-on therapy in essential hypertension
2010-023606-13Phase 4Active
- Sponsor
- GiEnne Pharma
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydroxyprogesterone caproate in essential hypertension (2 arms), sponsored by GiEnne Pharma. Started Dec 2010; status: active.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2010-023606-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023606-13.